Registration Options

Activity Dates: 02/23/2022 - 02/23/2024

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

In the era of shared decision-making, ensuring patients and families understand the relative risk and statistical concept of number needed to treat for understanding efficacy and side effect liabilities may help empower patients to improve adherence. This program will help ensure psychiatric pharmacists and other health care professionals using antipsychotic treatments understand the benefits and drawbacks to newer antipsychotics and can help best place these “third-generation” antipsychotic treatments in treatment plans that may improve overall patient outcomes.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor.
Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at http://cpnp.org/mycpnp/transcript/acpe.

Faculty Information and Disclosures

Leslie Citrome, MD, MPH
Steven C. Stoner, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Discuss the receptor binding profile of trace amine associated receptor 1 (TAAR1) agonists in development and compare findings to first and second-generation antipsychotics.
  2. Summarize the relationship between trace amines and TAAR1 receptors in cell signaling.
  3. Discuss mechanistic theories as to how TAAR1 agonist activity downregulates dopamine transmission and may be useful in the future treatment of schizophrenia. 
  4. Review the findings of available clinical trial data regarding the safety and efficacy of TAAR1 agonists in the treatment of schizophrenia.

 

Continuing Education Credit and Disclosures

Activity Dates: 02/23/2022 - 02/23/2024
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-060-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Grant Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.